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BACKGROUND
Whether remote ischemic preconditioning (transient ischemia and reperfusion of 
the arm) can improve clinical outcomes in patients undergoing coronary-artery 
bypass graft (CABG) surgery is not known. We investigated this question in a 
randomized trial.
METHODS
We conducted a multicenter, sham-controlled trial involving adults at increased 
surgical risk who were undergoing on-pump CABG (with or without valve surgery) 
with blood cardioplegia. After anesthesia induction and before surgical incision, 
patients were randomly assigned to remote ischemic preconditioning (four 5-minute 
inflations and deflations of a standard blood-pressure cuff on the upper arm) or 
sham conditioning (control group). Anesthetic management and perioperative care 
were not standardized. The combined primary end point was death from cardio-
vascular causes, nonfatal myocardial infarction, coronary revascularization, or 
stroke, assessed 12 months after randomization.
RESULTS
We enrolled a total of 1612 patients (811 in the control group and 801 in the 
ischemic-preconditioning group) at 30 cardiac surgery centers in the United King-
dom. There was no significant difference in the cumulative incidence of the primary 
end point at 12 months between the patients in the remote ischemic precondition-
ing group and those in the control group (212 patients [26.5%] and 225 patients 
[27.7%], respectively; hazard ratio with ischemic preconditioning, 0.95; 95% con-
fidence interval, 0.79 to 1.15; P = 0.58). Furthermore, there were no significant 
between-group differences in either adverse events or the secondary end points of 
perioperative myocardial injury (assessed on the basis of the area under the curve 
for the high-sensitivity assay of serum troponin T at 72 hours), inotrope score 
(calculated from the maximum dose of the individual inotropic agents administered 
in the first 3 days after surgery), acute kidney injury, duration of stay in the inten-
sive care unit and hospital, distance on the 6-minute walk test, and quality of life.
CONCLUSIONS
Remote ischemic preconditioning did not improve clinical outcomes in patients 
undergoing elective on-pump CABG with or without valve surgery. (Funded by the 
Efficacy and Mechanism Evaluation Program [a Medical Research Council and 
National Institute of Health Research partnership] and the British Heart Founda-
tion; ERICCA ClinicalTrials.gov number, NCT01247545.)
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Coronary heart disease is the lead-ing cause of death and disability world-wide. For patients with multivessel coro-
nary artery disease, the treatment of choice for 
many is revascularization by means of coronary-
artery bypass grafting (CABG) surgery. As a re-
sult of the aging of the population, an increased 
prevalence of coexisting conditions (e.g., diabe-
tes, obesity, and hypertension), and a growing 
need for concomitant valve surgery, higher-risk 
patients are undergoing CABG surgery (with or 
without valve surgery); the clinical outcomes in 
such patients have been worse than the outcomes 
in patients without so many problems.1,2 Thus, 
novel cardioprotective interventions are indicat-
ed to improve clinical outcomes.
There is evidence that the heart and other 
organs can be protected against lethal acute 
ischemia–reperfusion injury by applying one or 
more cycles of brief, nonlethal ischemia and re-
perfusion to a remote organ or tissue, a procedure 
that has been termed remote ischemic precondi-
tioning.3-6 The mechanisms underlying remote 
ischemic preconditioning are incompletely under-
stood, although current concepts suggest that a 
bloodborne factor is produced in response to the 
remote ischemic preconditioning stimulus, which 
conveys the protective effect from the remote 
organ or tissue to the target organ.4,6 Remote 
ischemic preconditioning can be performed non-
invasively by simply inflating and deflating a 
standard blood-pressure cuff placed on the upper 
arm or thigh to induce transient ischemia and 
reperfusion,7 an intervention that has been shown 
to reduce the extent of perioperative myocardial 
injury in patients undergoing CABG surgery 
(with or without valve surgery).8-10 Whether re-
mote ischemic preconditioning can improve clin-
ical outcomes after cardiac surgery is not known. 
We conducted the Effect of Remote Ischemic 
Preconditioning on Clinical Outcomes in Patients 
Undergoing Coronary Artery Bypass Graft Sur-
gery (ERICCA) trial to investigate this question.11
Me thods
Trial Design
Our trial was a multicenter, randomized, sham-
controlled clinical study conducted at 30 cardiac 
surgery centers in the United Kingdom. The study 
was approved by the National Health Service 
Research Ethics Committee and was conducted 
in accordance with the principles of Good Clini-
cal Practice under the oversight of University Col-
lege London Hospital. All participants provided 
written informed consent. The London School of 
Hygiene and Tropical Medicine Clinical Trials 
Unit coordinated the trial. Details of the trial 
design have been reported previously.11 The study 
adhered to the protocol, which is available with 
the full text of this article at NEJM.org.
The authors designed the study and collected, 
analyzed, and interpreted the data. All the au-
thors wrote or contributed to the writing of the 
manuscript, made the decision to submit it for 
publication, and vouch for the accuracy and com-
pleteness of the data and analysis. The funding 
sources had no role in the study.
Participants
Eligible patients were adults (≥18 years of age) 
with an additive European System for Cardiac 
Operative Risk Evaluation (EuroSCORE) of 5 or 
higher (with higher scores indicating a greater 
risk of death; 0 indicates minimum risk and ≥6 
indicates high risk) who were undergoing on-
pump CABG (with or without valve surgery) with 
myocardial protection provided by blood cardio-
plegia. Exclusion criteria were cardiogenic shock 
or cardiac arrest during the current admission, 
pregnancy, clinically significant peripheral arte-
rial disease affecting the arms, hepatic dysfunc-
tion (bilirubin level of >20 μmol per liter [1.2 mg 
per deciliter] or international normalized ratio 
of >2.0), pulmonary disease (forced expiratory 
volume in 1 second of <40% of the predicted 
value) or renal failure (estimated glomerular fil-
tration rate of <30 ml per minute per 1.73 m2 of 
body-surface area), and concomitant therapy 
with glibenclamide or nicorandil (medications 
that may interfere with remote ischemic precon-
ditioning). Participants underwent follow-up 
assessments at 6 weeks (performed at the time 
of the routine outpatient clinic visit) and at 12 
months (performed mainly by telephone contact 
with the patient or review of the general practi-
tioner’s notes, since there was no routine outpa-
tient clinic visit at this time point).
Randomization
Patients were randomly assigned in a 1:1 ratio to 
undergo either remote ischemic preconditioning 
or sham preconditioning (control group). Ran-
domization was conducted by means of a secure 
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website (Sealed Envelope) and was stratified ac-
cording to recruiting center. The patients, anes-
thesiologists, cardiac surgeons, intensive care 
unit (ICU) and ward staff, and study investiga-
tors collecting and analyzing the data were all 
unaware of the treatment assignments.
Interventions
For participants who were randomly assigned to 
undergo remote ischemic preconditioning, a 
standard blood-pressure cuff was placed on the 
upper arm, inflated to 200 mm Hg, and left in-
flated for 5 minutes. The cuff was then deflated 
to 0 mm Hg and left uninflated for 5 minutes. 
This cycle was performed four times in total. If the 
systolic pressure was higher than 185 mm Hg, 
the cuff was inflated to 15 mm Hg above the 
systolic pressure. The protocol for the control 
group comprised four 5-minute cycles of simu-
lated remote ischemic preconditioning. Cuff in-
flation was simulated by inflating the cuff with 
the valve open; this prevented actual inflation of 
the cuff. After 5 minutes, the air valve was 
closed and left closed for 5 minutes, correspond-
ing to cuff deflation. Remote ischemic precondi-
tioning and sham preconditioning were per-
formed after anesthesia induction and before 
surgical incision.
Surgical Procedure
Anesthetic management and perioperative care 
were not standardized. Arterial blood pressure, 
central venous pressure, electrocardiographic trac-
ings, and nasopharyngeal temperature were re-
corded continuously. Intravenous glyceryl trini-
trate was used only when clinically indicated, 
since it may interfere with the cardioprotective 
effect of remote ischemic preconditioning. After 
the institution of standard nonpulsatile cardio-
pulmonary bypass, all coronary-artery bypass 
grafts were constructed while blood cardiople-
gia was being used for myocardial protection. 
After the anastomoses of the grafts (with or 
without valve replacement or repair), cardiopul-
monary bypass was discontinued and protamine 
was used to reverse the effect of heparin.
Outcomes
The primary study end point was the rate of 
major adverse cardiac and cerebral events, as-
sessed within 12 months after randomization. 
These comprised death from cardiovascular 
causes, nonfatal myocardial infarction, coronary 
revascularization, or stroke. All primary events 
were validated by an independent event valida-
tion committee. Definitions of the major clinical 
end points are provided in the Methods section 
in the Supplementary Appendix, available at 
NEJM.org.
Secondary end points included components of 
the primary end point, assessed at 30 days and 
12 months, and death from any cause, assessed 
at 12 months. Additional secondary end points 
were perioperative myocardial injury (assessed 
on the basis of the area under the curve [AUC] 
at 72 hours for the results of a high-sensitivity 
troponin T assay [normal troponin T range, 0 to 
14 ng per liter] in blood samples obtained pre-
operatively and 6, 12, 24, 48, and 72 hours after 
cardiac bypass); grade 1, 2, or 3 acute kidney 
injury within 72 hours after surgery (assessed on 
the basis of the increase in the serum creatinine 
level according to the International Kidney Dis-
ease: Improving Global Outcomes classifica-
tion12); serum creatinine level at 6 weeks and 
12 months; 24-hour AUC for plasma neutrophil 
gelatinase–associated lipocalin (NGAL, calculat-
ed from blood samples taken preoperatively and 
at 6, 12, and 24 hours after cardiac bypass; nor-
mal range, 0 to 1000 ng per liter); maximum 
inotrope score in the 72-hour postoperative 
period (an assessment of hemodynamic stability 
calculated from the maximum dose of the indi-
vidual inotropic agents administered in the first 
3 days after surgery13); length of ICU stay and 
hospital stay; 6-minute walk test at baseline, 
6 weeks, and 12 months; and health-related qual-
ity of life as assessed by the European Quality of 
Life–5 Dimensions score at baseline, 6 weeks, 
and 3, 6, 9, and 12 months.
Statistical Analysis
On the basis of previous data,14,15 we estimated 
that 20% of participants in the control group 
would have major adverse cardiac or cerebral 
events within 12 months. To detect a 27% rela-
tive reduction in this primary end point in the 
ischemic-preconditioning group (from 20.0% to 
14.6%), with a power of 80% and a significance 
level of 5%, we calculated that a sample of 770 
patients would be required for each study group, 
or 1540 in total. To allow for dropouts (4.5%) 
this total was increased to 1610 patients (805 
patients in each group).
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The primary analysis compared the cumula-
tive incidence of major adverse cardiac or cere-
bral events at 12 months between the ischemic-
preconditioning and control groups, with the use 
of Cox proportional-hazards models and with 
censoring of data at the date of the adverse 
event, loss to follow-up, or withdrawal from the 
study or at 12 months. The difference in treat-
ment effect between subgroups was examined 
by including an interaction between the treat-
ment group and the subgroup variable. The pri-
mary analysis was conducted on an intention-to-
treat basis and included all participants. We also 
carried out a per-protocol analysis, which was 
restricted to participants who underwent remote 
ischemic preconditioning or sham precondition-
ing as specified by the protocol and underwent 
CABG surgery (with or without valve surgery).
To compare subgroups with respect to the 
effect of treatment on the incidence of major 
adverse cardiac and cerebral events, we included 
an interaction between treatment group and the 
subgroup variable in the time-to-event model. 
Time-to-event methods were used to evaluate ma-
jor adverse cardiac and cerebral events at 30 days, 
components of the primary end point at 30 days 
and 12 months, and deaths from any cause at 
12 months. Simple linear regression was used 
for between-group comparisons of the natural 
logarithm of the AUC for troponin T at 72 hours 
and the AUC for NGAL at 24 hours. Nonpara-
metric tests were used to compare the ischemic-
preconditioning and control groups with respect 
to acute kidney injury and inotrope score. Propor-
tional-hazards models accounting for the com-
peting risk of death were used for hospital stay 
and ICU stay. Analysis of covariance, with adjust-
ment for baseline values, was performed to evalu-
ate the quality of life at baseline, at 6 weeks, and 
at 3, 6, 9, and 12 months and the serum creati-
nine level at 6 weeks and 12 months. For quality 
of life, we used nonparametric confidence inter-
vals because of the nonnormal distribution. A 
linear mixed model with unstructured residuals 
was used to compare the mean distance on the 
6-minute walk test between the two study groups 
at 6 weeks and 12 months. Logistic regression 
was performed for between-group comparisons 
of the proportion of participants with postop-
erative atrial fibrillation, which was a post hoc 
outcome. Initial models included only participants 
for whom all data were available (complete-case 
analysis). For the complete-case analysis of the 
high-sensitivity assay for troponin T and of NGAL, 
data had to be available for all time points; for 
the complete-case analysis of serum creatinine, 
data had to be available at baseline and at the 
relevant follow-up visit. We evaluated the effect 
of missing data by using multiple imputation to 
replace any missing values for high-sensitivity 
troponin T assays, NGAL, and serum creatinine. 
Full details of the statistical methods, including 
the imputation model, are provided in the Meth-
ods section in the Supplementary Appendix.
R esult s
Study Population
Between April 2011 and March 2014, we enrolled 
1612 patients undergoing on-pump CABG (with 
or without valve surgery) with blood cardioplegia 
(811 assigned to sham conditioning and 801 to 
remote ischemic preconditioning) (Fig. S1 in the 
Supplementary Appendix). Detailed screening logs 
of 1 month’s duration were obtained for 3 sepa-
rate, randomly selected months during the 
36-month recruitment period. Of the 1869 pa-
tients who were screened during the 3 months, 
414 (22.2%) were eligible for inclusion in the study, 
and 195 of the eligible patients (47.1%) were ran-
domly assigned to a study group. A EuroSCORE 
of less than 5 was the main reason for ineligi-
bility.
The treatment groups were well balanced 
with respect to baseline characteristics, surgical 
details, and use of cardiovascular medications 
during follow-up (Table 1, and Tables S1, S2, and 
S3 in the Supplementary Appendix). The inter-
vention was completed according to the protocol 
for 716 (88.3%) of the participants in the control 
group and 691 (86.3%) of those in the ischemic-
preconditioning group; reasons for incomplete 
intervention are provided in Figure S1 in the 
Supplementary Appendix. The mean (±SD) time 
between the start of preconditioning and initia-
tion of cardiac bypass was 1.8±0.6 hours in the 
control group and 1.7±0.7 hours in the ischemic-
preconditioning group. Relatively few partici-
pants were lost to follow-up before 12 months 
for reasons other than death: 28 (3.5%) in the 
control group and 19 (2.4%) in the ischemic-
preconditioning group (Fig. S1 in the Supple-
mentary Appendix). All 1612 patients were in-
cluded in the analysis of the primary outcome.
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Outcomes
There was no significant difference between the 
ischemic-preconditioning group and the control 
group with respect to the primary end point 
(proportion of participants with a major adverse 
cardiac or cerebral event at 12 months, 26.5% 
[212 participants] and 27.7% [225 participants], 
respectively; hazard ratio with ischemic precon-
ditioning, 0.95; 95% confidence interval [CI], 
0.79 to 1.15; P = 0.58) (Table 2 and Fig. 1, and 
Table S4 in the Supplementary Appendix). There 
was no evidence of a significant difference be-
tween the control group and the ischemic-condi-
tioning group in any of the individual compo-
nents of the primary end point (death from 
cardiovascular causes, nonfatal myocardial in-
farction, stroke, or coronary revascularization) 
(Table 2, and Figs. S2, S3, and S4 and Table S5 
in the Supplementary Appendix).
Results of the per-protocol analysis were very 
similar to those of the intention-to-treat analy-
sis, showing little difference in the incidence of 
major adverse cardiac and cerebral events be-
tween the ischemic-preconditioning and control 
groups. In the per-protocol analysis, 28.5% of 
participants (204 of 717) in the ischemic-precon-
ditioning group had major adverse cardiac and 
cerebral events within 12 months, as compared 
with 27.2% (188 of 691) in the control group 
(hazard ratio, 0.95; 95% CI, 0.78 to 1.16; P = 0.64). 
There was no evidence that the effect of remote 
ischemic preconditioning as compared with the 
effect of sham preconditioning differed signifi-
cantly within the subgroups for any of the pre-
specified end points (Fig. 2). Post hoc subgroup 
analyses showed no evidence that the effect of 
remote ischemic preconditioning on the primary 
composite end point differed significantly ac-
cording to the type of anesthetic used during 
surgery or the interval between the start of re-
mote ischemic preconditioning and initiation of 
cardiac bypass (Table S6 in the Supplementary 
Appendix).
Secondary Outcomes
The complete-case analysis, which included 728 
patients with full data on perioperative myocar-
dial injury (45.2% of all 1612 patients), suggest-
ed a 10% lower AUC for the troponin T level in 
patients undergoing remote ischemic precondi-
tioning as compared with those undergoing 
sham preconditioning (geometric mean, 32.7 vs. 
36.4 ng · hour per milliliter; ratio, 0.90; 95% CI, 
0.81 to 0.99). However, this effect largely disap-
peared when multiple imputation analyses were 
undertaken (geometric mean, 34.2 vs. 34.8 
ng · hour per milliliter; ratio, 0.98; 95% CI, 0.91 
to 1.06) (Table 2). This lack of effect was sup-
Characteristic
Control 
(N = 811)
RIPC 
(N = 801)
Patients
Male sex — no./total no. (%) 586/806 (72.7) 556/790 (70.4)
Age — yr 76.3±7.0 76.1±6.1
EuroSCORE†
Median 6 6
Range 5–16 5–17
Prior diagnoses — no./total no. (%)
Diabetes mellitus 211/807 (26.1) 203/790 (25.7)
Hypercholesterolemia 555/807 (68.8) 570/790 (72.2)
Hypertension 599/807 (74.2) 602/790 (76.2)
Myocardial infarction 309/807 (38.3) 328/790 (41.5)
Sulfonylurea — no./total no. (%) 49/807 (6.1) 42/791 (5.3)
Surgery
CABG completed — no./total (%) 776/805 (96.4) 772/789 (97.8)
Valve surgery — no./total no. (%) 406/775 (52.4) 371/772 (48.1)
Cross-clamp time — min‡
Median 71 69
Range 15–292 18–324
Cardiopulmonary-bypass time — min§
Median 107 105
Range 29–422 34–585
Anesthetics — no./total no. (%)
Volatile, without propofol 11/767 (1.4) 12/769 (1.6)
Volatile, with propofol 312/767 (40.7) 313/769 (40.7)
Propofol, without volatile 397/767 (51.8) 409/769 (53.2)
Other — no propofol or volatile 47/767 (6.1) 35/769 (4.6)
Intravenous nitrates — no./total no. (%) 230/775 (29.7) 233/772 (30.2)
*  Plus–minus values are means ±SD. Additional patient and surgical character-
istics are provided in Tables S1 and S2 in the Supplementary Appendix. CABG 
denotes coronary-artery bypass grafting, and RIPC remote ischemic precondi-
tioning.
†  In the European System for Cardiac Operative Risk Evaluation (EuroSCORE), 
higher scores indicate a greater risk of death; 0 indicates minimum risk and 
≥6 indicates high risk. Data were available for 806 participants in the control 
group and 790 in the RIPC group.
‡  Data were available for 734 participants in the control group and 735 in the 
RIPC group.
§  Data were available for 750 participants in the control group and 757 in the 
RIPC group.
Table 1. Baseline Characteristics of the Patients and Surgical Characteristics.*
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Outcome
Control 
(N = 811)
RIPC 
(N = 801)
Treatment Effect, 
Control vs. RIPC 
(95% CI) P Value
Primary end point
MACCE within 12 mo 225 (27.7) 212 (26.5) 0.95 (0.79–1.15) 0.58
Death from cardiovascular causes — 
no. (%)
32 (3.9) 47 (5.9) 1.50 (0.96–2.35) 0.08
Myocardial infarction 191 (23.6) 173 (21.6) 0.91 (0.74–1.12) 0.39
Stroke 16 (2.0) 17 (2.1) 1.08 (0.55–2.14) 0.82
Coronary revascularization  3 (0.4)  2 (0.2) 0.68 (0.11–4.09) 0.68
Secondary end points
AUC for troponin T — ng · hr/ml
Median (IQR) 35.7 (22.8–57.3) 30.1 (20.3–53.9)
Geometric mean 36.4±2.0 32.7±2.0
No. with complete data set 367 361 0.90 (0.81–0.99) 0.03
Total no. with multiple imputation 798 782 0.98 (0.91–1.06) 0.63
Inotrope score†
Median (IQR) 6 (0–16) 6 (0–15) NA 0.92
No. with data available 794 775
Acute kidney injury — no./total no. (%)‡ 293/772 (38.0) 287/749 (38.3) NA 0.98
Grade 1 226/772 (29.3) 230/749 (30.7)
Grade 2 44/772 (5.7) 38/749 (5.1)
Grade 3 23/772 (3.0) 19/749 (2.5)
Hospital stay — days
Median (IQR) 10 (7–17) 10 (7–16) NA 0.36
No. with data available 775 758
ICU stay — days
Median (IQR) 3 (1–5) 2 (1–4) NA 0.35
No. with data available 775 758
Distance on 6-min walk test — m
At 6 wk 335±125 332±109 −4 (−24 to 7) 0.72
At 12 mo 365±128 386±116 23 (2 to 44) 0.03
No. with data available 402 383
*  Plus–minus values are means ±SD. The treatment effect was calculated as the hazard ratio for the primary end point 
and as the ratio of geometric means for all the secondary end points except the distance on the 6-minute walk test, for 
which the treatment effect was calculated as the difference in means. More detailed data and other outcomes are pro-
vided in Tables S4 and S5 in the Supplementary Appendix. AUC denotes area under the curve, CI confidence interval, 
ICU intensive care unit, IQR interquartile range, MACCE major adverse cardiac and cerebral events, and NA not appli-
cable.
†  Inotrope score was calculated from the maximum dose of the individual inotropic agents administered during the first 
72 hours after surgery.13 The scale ranges from 0 to no upper limit, with higher scores indicating greater hemodynamic 
instability.
‡  Grade 1, 2, or 3 acute kidney injury within 72 hours after surgery was assessed on the basis of the increase in the serum 
creatinine level according to the International Kidney Disease: Improving Global Outcomes classification.12
Table 2. Clinical Outcomes and Treatment Effect.*
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ported by examination of the data for the 1282 
patients (79.5%) who had at least one periop-
erative high-sensitivity troponin T assay result, 
which showed little difference at any time point 
between the ischemic-preconditioning and con-
trol groups (full details on patterns of missing 
data are provided in Table S7 in the Supplemen-
tary Appendix). Post hoc subgroup analyses 
showed no evidence that the effect of remote 
ischemic preconditioning on perioperative myo-
cardial injury differed according to the type of 
anesthetic used during surgery or the interval 
between the start of remote ischemic precondi-
tioning and initiation of cardiac bypass (Table S6 
in the Supplementary Appendix).
The distance walked on the 6-minute walk 
test at 12 months was greater for participants in 
the ischemic-preconditioning group than for those 
in the control group (Table 2), although this 
finding should be interpreted with caution, 
since only 785 participants completed one or 
more of the three protocol-specified 6-minute 
walk tests (at baseline, 6 weeks, or 12 months), 
and of these participants, only 360 completed 
the 6-minute walk test at 12 months. There was 
no evidence of any effect of remote ischemic 
preconditioning on any of the other secondary 
end points (Table 2, and Table S8 in the Supple-
mentary Appendix).
Adverse Events
The proportion of participants with adverse 
events was similar in the ischemic-precondition-
ing and control groups (364 of 801 participants 
[45.4%] and 354 of 811 [43.6%], respectively) 
(Table 3). More participants in the ischemic-
preconditioning group than in the sham-condi-
tioning group had skin petechiae at the time of 
the intervention (35 of 801 participants [4.4%] 
vs. 2 of 811 [0.2%]); there were no long-term 
consequences in either group. Three unexpected 
serious adverse events occurred at the time of 
the study intervention. Only one of these events 
was thought to be related to the intervention — 
the blood-pressure cuff used in the ischemic-
preconditioning intervention remained inflated 
during surgery, but this had no long-term con-
sequences. The other two events, arm twitching 
and arm weakness or altered sensation, were 
thought to be unrelated to the intervention. A 
similar proportion of participants in the isch-
emic-preconditioning and sham-preconditioning 
groups had adverse events after the intervention 
(349 of the 801 participants assigned to remote 
ischemic preconditioning [43.6%] and 353 of the 
811 assigned to the sham conditioning [43.5%]); 
none of these events were thought to be related 
to the intervention. Unexpected serious adverse 
events included heart failure, cardiac arrest, col-
lapse or fall, diarrhea, noncardiac chest pain, 
shortness of breath, multiorgan failure, pulmo-
nary edema, cancer (nonfatal), and confusion. 
Although there was a trend toward an increase 
in the rate of death from cardiovascular causes 
in association with remote ischemic precondi-
tioning as compared with sham conditioning, 
the evidence for a difference was weak, and the 
study was not powered to detect this individual 
end point.
Discussion
In higher-risk patients undergoing on-pump 
CABG (with or without valve surgery) with blood 
cardioplegia, remote ischemic preconditioning 
Figure 1. Cumulative Incidence of Major Adverse Cardiac and Cerebral 
Events (MACCE) at 12 Months.
There was no significant difference in the primary end point (the incidence 
of combined cardiac and cerebral events at 12 months) between participants 
assigned to remote ischemic preconditioning (RIPC group) and those 
 assigned to sham preconditioning (control group).
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did not affect the incidence of major adverse 
cardiac and cerebral events at 12 months, as 
compared with sham preconditioning. Further-
more, remote ischemic preconditioning had no 
effect on any of the major secondary end points, 
as compared with sham preconditioning.
In two recent studies, analysis of secondary 
end points showed beneficial effects of remote 
ischemic conditioning on short-term clinical 
outcomes16 and long-term clinical outcomes17 
after cardiac surgery, although the studies were 
not adequately powered to assess these end 
points. Recent clinical trials that were prospec-
tively designed and adequately powered failed to 
show any beneficial effect of remote ischemic 
preconditioning on inpatient clinical outcomes 
among 299 children (primary end point, the 
duration of the postoperative hospital stay)18 and 
1280 adults (combined primary end point, death, 
myocardial infarction, arrhythmia, stroke, coma, 
renal failure, respiratory failure, cardiogenic 
shock, gastrointestinal complication, or multi-
organ failure).19
Studies assessing the effect of remote ische-
mic preconditioning on perioperative myocardi-
al injury (measured on the basis of serum car-
diac biomarker release), a surrogate end point 
for cardioprotection that has been associated 
with worse clinical outcomes after surgery, have 
had mixed results.8-10,16,20,21 In our trial, we were 
unable to show a clinically significant reduction 
in perioperative myocardial injury, although this 
result should be interpreted with caution be-
cause of missing data.
At some point during surgery, almost 90% of 
the patients in our trial received propofol, an 
anesthetic agent that has been reported to at-
tenuate the cardioprotective efficacy of remote 
ischemic preconditioning during cardiac sur-
gery.22-24 Use of propofol in most study partici-
pants appears to be a common denominator in 
many of the studies that have shown no signifi-
cant cardioprotective benefit of remote ischemic 
preconditioning.25
In our study, there was a suggestion of an 
increased risk of death from cardiovascular 
causes in association with remote ischemic pre-
conditioning as compared with the sham precon-
ditioning. However, our study was not powered 
to detect a difference in this individual end point, 
Figure 2. Incidence of Major Adverse Cardiac and Cerebral Events at 12 Months in Prespecified Subgroups.
Subgroup analyses showed no significant differences in major adverse cardiac and cerebral events at 12 months 
 between participants assigned to RIPC and those assigned to the control group.
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and the finding should therefore be interpreted 
with caution. In a post hoc subgroup analysis 
involving patients undergoing off-pump cardiac 
surgery, Hong et al.19 found that remote ische-
mic preconditioning combined with postcondi-
tioning was associated with a significant in-
crease in the composite outcome of inpatient 
major adverse events. In a 58-patient study by 
Lucchinetti et al.,26 remote ischemic precondi-
tioning was associated with an increase in the 
secondary perioperative composite end point of 
myocardial infarction and new arrhythmias, as 
compared with the control group, although there 
was no significant between-group difference in 
cardiovascular outcomes at 6 months. Further-
more, remote ischemic preconditioning was also 
associated with increased expression of gene 
sets related to tumor-necrosis-factor signaling, 
stem-cell and progenitor-cell activity, and hyper-
trophy. However, the overwhelming majority of 
previously published studies17,18 and meta-analy-
ses27-30 have not shown any harmful effects of 
remote ischemic preconditioning during cardiac 
bypass surgery, and in fact, one recent study 
showed a reduction in all-cause mortality with 
remote ischemic preconditioning.17
Limitations of the current study include the 
lack of standardization of preoperative and peri-
operative anesthesia and medication, since we 
wanted to reflect the current clinical practice of 
cardiac surgery as much as possible, and incom-
plete data for some secondary end points. In ad-
dition, the anesthesiologists may not have been 
completely unaware of the study-group assign-
ments. Since we did not collect data on fluid 
management (blood transfusion and administra-
tion of crystalloids and colloids), the inotrope 
data should be interpreted with caution. To in-
vestigate further the effect of the missing data 
on the results, we used multiple imputation. For 
unbiased results, this approach requires the as-
sumption that data are missing completely at 
random given the variables included in the im-
putation model, rather than the more stringent 
assumption that data are missing completely at 
random, which is required for unbiased results 
with complete-case analysis. Finally, an echocar-
diographic substudy had been planned, but be-
cause of logistical issues, very few patients were 
included in the substudy; thus, no meaningful 
data on left ventricular function were available 
for analysis.
In conclusion, our study shows that in higher-
risk patients undergoing on-pump CABG (with 
or without valve surgery) with blood cardiople-
gia, the addition of remote ischemic precondi-
tioning (with transient arm ischemia and reper-
fusion) did not provide greater cardioprotection 
than sham control and, accordingly, did not im-
prove clinical outcomes at 12 months.
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Event
Control 
(N = 811)
RIPC 
(N = 801)
no. of participants (%)
Any adverse event 354 (43.6) 364 (45.4)
Adverse event during RIPC or sham 
preconditioning
3 (0.4) 37 (4.6)
Unexpected adverse event 1 (0.1) 2 (0.2)
Skin petechiae 2 (0.2) 35 (4.4)
Adverse event after intervention 353 (43.5) 349 (43.6)
Death 55 (6.8) 71 (8.9)
Hospital admission 267 (32.9) 257 (32.1)
Other 88 (10.9) 80 (10.0)
Table 3. Adverse Events.
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